Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
FDA Clears First Oral GLP-1 for Weight Loss On December 22, 2025, the FDA approved Novo Nordisks once-daily Wegovy pill (25 mg semaglutide), the first oral GLP-1 receptor agonist indicated for chronic weight management and cardiovascular risk reduction in adults with obesity or overweight plus at least one weight-related comorbidity
They are environmental factors, diet, genetic defects, stress and drugs
If all goes well, youll get a tool that can recognize patterns or make predictions
Increasingly used to support weight loss (with several countries authorizing the prescription of Novo Nordisks Wegovy and Eli Lillys Zepbound/Mounjaro drugs for weight management), the companies behind these drugs are reporting rapid sales growth and have seen their share prices rise significantly
The Calorie Myth: Measurement and Reality
